Treating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
Michelle Dalton, ELS
Pharmacologic activity in the retina realm continues to hold much excitement for new therapies to treat retinal disorders.
The advent of three-dimensional optical coherence tomography to live surgery may bring greater clarity to how ophthalmologists visualize structures and how they operate.